Actively Recruiting
Evaluation of BG-C477 Safety, Pharmacokinetics, and Antitumor Effects in Adults with Selected Advanced Solid Tumors Using Monotherapy and Combination Treatments
Led by BeOne Medicines · Updated on 2026-10-28
310
Participants Needed
59
Research Sites
N/A
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating BG-C477, a targeted antibody-drug conjugate, in adults with advanced solid tumors that cannot be removed by surgery or have spread to other parts of the body. This Phase 1ab study aims to assess the safety, tolerability, pharmacokinetics, pharmacodynamics, and early antitumor activity of BG-C477 alone and in combination with other anticancer agents. BG-C477 targets a protein called CEA on lung cancer cells to deliver a drug that prevents cancer cell multiplication and causes cell death. The study includes two parts Phase 1a tests increasing doses of BG-C477 alone to find a safe dose without serious side effects. Phase 1b evaluates the selected dose further, either alone or combined with chemotherapy or tislelizumab. BG-C477 is administered intravenously. Participants receive treatment during these phases, with sequential dose escalation and expansion cohorts. The treatment duration is about 9 months for Phase 1a and approximately 18 months for Phase 1b. Participants will attend regular clinic visits for treatment administration, health assessments, blood tests, tumor evaluations, and imaging studies. Researchers will monitor adverse events, determine the recommended dose levels, and assess tumor response and progression using standardized criteria. Safety and pharmacokinetic data will be collected up to about two years after the last dose. Overall participation lasts up to 18 months depending on the study phase.
CONDITIONS
Brief Title
A Study of BG-C477 in Participants With Advanced Solid Tumors
Research Team
S
Study Director
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here